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Abstract
Background: The aim of this study was to assess the safety and efficacy of switching therapy from low molecular
weight heparin (LMWH; enoxaparin) to dabigatran for prevention of venous thromboembolic events (VTE) in
patients undergoing elective total hip or knee replacement surgery (THR/TKR).
Methods: This was a prospective, multicenter, open-label, single-arm, observational, study in patients undergoing
THR or TKR who were to receive enoxaparin 40 mg for thromboprophylaxis. Enoxaparin was initiated before or after
surgery according to local practice, and was switched to dabigatran 220 mg once daily at a time point chosen by
the investigator. The coprimary endpoints were major bleeding events, and the composite of symptomatic VTE and
all-cause mortality, from last use of enoxaparin to 24 h after last intake of dabigatran.
Results: Altogether, 168 (81 THR, 87 TKR) patients were enrolled, of whom 161 received both enoxaparin and
dabigatran, 2 received dabigatran only and 5 received enoxaparin only. The median time of the first dabigatran
tablet was 24.0 h after the last LMWH dosage and the median number of days on dabigatran treatment was
36 days. No symptomatic VTE or death occurred during the study. One major bleeding event was seen at the
surgical site and required treatment cessation. Three minor bleeding events were observed.
Conclusions: In the normal clinical setting, switching from LMWH to dabigatran in patients who had undergone
THR and TKR was safe and effective in preventing VTE. The reported adverse events and serious adverse events
were consistent with the known safety profile for dabigatran. Switching from a subcutaneous to an oral
anticoagulant may offer greater convenience in the outpatient setting after discharge.
Trial registration: ClinicalTrials.gov identifier NCT01153698.
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Background
Without thromboprophylaxis, major orthopedic sur-
gery, such as total hip or knee replacement (THR or
TKR), carries a high risk of venous thromboembolic
events (VTE), which manifests as deep vein thrombosis
(DVT) in two-thirds and as pulmonary embolism (PE) in
approximately one-third of patients [1]. This is because
orthopedic surgery induces local and systemic thrombin
generation, which can trigger thrombus formation and
thrombotic events. Without thromboprophylaxis, veno-
graphic DVT can be observed in 40–80 % of patients [2].
The risk of nonfatal versus fatal PE for elective orthopedic
surgery patients without thromboprophylaxis is 1.8–7.0 %
and 0.2–0.7 %, respectively [3].
Effective anticoagulation significantly reduces the risk
of VTE and is recommended in various international
consensus guidelines [4, 5]. Therefore, the majority of
patients receive some kind of thromboprophylaxis; low
molecular weight heparin (LMWH) is commonly used
in many countries in Europe [6, 7]. However, as many
as 40 % of patients do not receive appropriate throm-
boprophylaxis as recommended by consensus guide-
lines mentioned above [8, 9]. The subcutaneous route
of administration for LMWH presents as a barrier to
applying the more effective extended prophylaxis regi-
mens up to 35 days after THR, and many patients do
not continue anticoagulant prophylaxis after discharge
from hospital [10]. Bjørnarå BT, et al. showed that
most cases of VTE after orthopedic surgery developed
following hospital discharge, confirming the need for
continued thromboprophylaxis [11]. Use of an oral
therapy simplifies and optimizes posthospital manage-
ment for these patients and enables continuation of
thromboprophylactic therapy for the recommended
time of up to 35 days [4, 12].
The non-vitamin K antagonist oral anticoagulant
(NOAC), dabigatran etexilate (henceforth, “dabigatran”),
is a reversible direct thrombin inhibitor, approved in
many regions or countries including Europe, Canada,
and Australia for this indication; it has recently been in-
cluded in guidelines for the prevention of VTE in pa-
tients undergoing orthopedic surgery [4]. Dabigatran
offers potential advantages over currently available antico-
agulants. It eliminates the need for parenteral or subcuta-
neous administration, increasing compliance particularly
when outpatient antithrombotic treatment is required
after early hospital discharge.
After major orthopedic surgery, dabigatran has favor-
able, slow postoperative onset with delayed absorption
and a reduced plasma peak concentration that does not
tend to disturb the ongoing hemostatic process [13, 14].
The results from randomized phase 3 trials (RE-NOV-
ATE®, RE-NOVATE™ II, and RE-MODEL™) in elective
major orthopedic surgery showed that dabigatran (150 mg
and 220 mg once daily [qd]) has similar efficacy compared
with enoxaparin 40 mg qd in adults [15–18].
The optimal start of thromboprophylaxis with LMWH
in orthopedic surgery remains unclear; even guidelines are
vague in this respect [4, 12]. In Europe, many orthopedic
departments start perioperative prophylaxis with LMWH
between 2 h before and 6 h after surgery, whereas others
start prophylaxis 12 h preoperatively [19, 20]. A periopera-
tive start is apparently more effective, but this is counter-
balanced by a marked increase in the risk of major
bleeding in comparison with a preoperative or postopera-
tive regimen [21]. Unlike LMWH, oral prophylaxis with
dabigatran is recommended to be initiated postsurgery.
Patients should have sufficient hemostasis before therapy
is initiated, and the recommendation is to start dabigatran
therapy with a half dose 1–4 h postsurgery [22, 23].
The primary objective of this trial was to assess the
safety (major bleeding events) and efficacy (symptomatic
VTE and all-cause mortality) of a switch from enoxaparin
40 mg qd to dabigatran 220 mg qd for prevention of VTE
in patients undergoing elective THR or TKR. The doses
and administration schedules selected for this observa-
tional study reflect the European standard clinical doses
for primary VTE prevention in the orthopedic setting [4].
Methods
This was a multicenter, open-label, prospective, single-
arm, study conducted at 7 orthopedic centers in Austria.
The Institutional Review Board (Ethikkommission der
Medizinischen Universität Wien, Wien, Austria) granted
approval. All patients provided written, informed con-
sent. The study was monitored by an independent Data
and Safety Monitoring Committee. This study was regis-
tered in the ClinicalTrials.gov database with the identi-
fier number NCT01153698.
Eligible patients were men and women with ages
≥18 years, who had undergone elective primary THR or
TKR, and were to receive LMWH (enoxaparin 40 mg)
subcutaneously for thromboprophylaxis according to the
Committee for Medicinal Products for Human Use label.
This study was terminated prior to reaching the target
sample size due to slower than anticipated recruitment.
The primary safety variable was major bleeding events
(MBEs) from last application of enoxaparin until 24 h
after last intake of dabigatran. MBEs were, as in phase 3
clinical trials, defined according to International Society
on Thrombosis and Haemostasis criteria: a bleed was con-
sidered major if ≥1 of the following criteria was met: fatal
bleeding; clinically overt bleeding in excess of what was
expected and associated with ≥20 g/L (corresponds to
1.24 mmol/L) fall in hemoglobin in excess of what was ex-
pected; clinically overt bleeding in excess of what was ex-
pected and leading to transfusion of ≥2 units packed cells
or whole blood in excess of what was expected;
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symptomatic documented retroperitoneal, intracranial, in-
traocular, or intraspinal bleeding; bleeding requiring treat-
ment cessation or, bleeding leading to reoperation. The
co-primary efficacy variable was the composite of docu-
mented symptomatic VTE and all-cause mortality from
last application of parenteral anticoagulant until 24 h after
last intake of dabigatran.
Patients started treatment with enoxaparin 40 mg qd ac-
cording to local clinical practice. Treatment with enoxa-
parin was initiated before or after THR or TKR surgery at
the clinical discretion of the investigator. The timepoint of
the switch was chosen by the investigator, based on clin-
ical judgment, as this was a noninterventional study [24].
If the switch was performed on the day after surgery or at
any later point in time, dabigatran was to be initiated with
220 mg, and not before the next scheduled dose of the
LMWH would have been due.
A total of 3 visits were to be scheduled. The first (base-
line) visit was to occur preoperatively ≤7 days before sur-
gery and was to include an assessment of creatinine
clearance for a dabigatran dosing decision according to
the Summary of Product Characteristics [23]. The second
visit was to be at the time of discharge from hospital or
24–48 h after the end of dabigatran treatment (whichever
came first). Visit 3 (follow-up visit) was only to be per-
formed if discharge from hospital occurred before the end
of dabigatran treatment, and was to occur 24–48 h after
the end of dabigatran treatment.
Patients were treated under the same surgical conditions
and techniques, according to hospital protocol. Any bleed-
ing event (i.e., major and nonmajor), symptomatic DVT
or PE events that occurred during the study period had to
be documented in the study case report form.
Statistical analyses were performed on data from all
patients treated, i.e., all patients who received ≥1 dose of
enoxaparin or dabigatran. The total treatment period is
defined as the period from the first application of enoxa-
parin 40 mg until 24 h after administration of the last
dose of dabigatran.
Due to the observational nature of this cohort study, all
analyses were descriptive in nature, including p-values and
confidence intervals (CIs) from statistical methods used
for exploratory purposes. For the analysis of the primary
endpoint, MBEs, and the number and percentage of pa-
tients with MBEs were presented including 2-sided 95 %
CI (exact interval by Pearson and Clopper).
Results
A total of 168 patients were enrolled and treated with
dabigatran and/or enoxaparin. All patients underwent ei-
ther TKR (51.8 %) or THR (48.2 %) surgery. Surgery was
completed in all patients as planned. Demographic and
baseline characteristics are given in Table 1. Overall,
57.1 % of patients were female, and patients ranged in
age from 28 to 84 (median, 62) years.
Concomitant cardiovascular medications, which are fre-
quently prescribed in the orthopedic population, were re-
ported in 93 (55.4 %) treated patients. Altogether, 161
patients received both enoxaparin and dabigatran; 2 re-
ceived dabigatran but not enoxaparin, and 5 received
enoxaparin but not dabigatran. Concerning enoxaparin
treatment, median number of days under enoxaparin
treatment was 2.0 days. Of the patients receiving enoxa-
parin, 31.9 % were treated for ≥4 days, 18.1 % for ≥7 days,
and 15.1 % for ≥10 days.
Of the 168 treated patients, 139 (85.3 %) patients com-
pleted dabigatran treatment as planned. Out of the
remaining 29 patients, 5 did not start dabigatran, and 24
prematurely discontinued treatment (12 due to adverse
events [AEs], 4 lost to follow-up, 2 refused to continue
taking dabigatran, 4 switched to other anticoagulants,
and 2 discontinued for other reasons).
Most treated patients (82.6 %) received their first oral
dose of dabigatran 22 to <26 h after the last dose of
enoxaparin, and most patients (88.7 %) received their
first oral dose of dabigatran ≥24 h after the end of sur-
gery (Table 2). The median time from last enoxaparin
dose to first oral dose of dabigatran was 24 h (range: 4–
48 h). Of patients treated with dabigatran, 84.7 % took
dabigatran for ≥28 days. The median number of days
under dabigatran treatment was 36 days which was com-
parable for THR and TKR patients (medians: 35.5 and
37 days, respectively).
There were no reported occurrences of symptomatic
VTE or all-cause mortality at any time during the study,
resulting in an estimated incidence for the composite ef-
ficacy endpoint of 0.0 %; the limited sample size resulted
in a wide 95 % CI (0.00-2.24).
The primary safety variable was MBEs from last appli-
cation of enoxaparin 40 mg until 24 h after last intake of
dabigatran. During this period, only 1 major bleeding
event occurred, and this was at the surgical site
(hematoma, resulting in an estimated incidence of MBE
of 0.61 % (95 % CI: 0.02-3.37). This MBE required treat-
ment cessation following TKR, but did not lead to a sig-
nificant drop in hemoglobin or require transfusion.
Overall, very few bleeding events were reported. From
last application of enoxaparin 40 mg until 24 h after last
intake of dabigatran, minor bleeding events were re-
ported in 3 additional patients. There were no major
extrasurgical-site bleeding events at any time during the
study. An additional minor bleeding event was reported
in a patient during enoxaparin treatment
During treatment with dabigatran, 44/163 (27.0 %) pa-
tients experienced ≥1 reported AE; of those, 13 (8.0 %) pa-
tients had AEs leading to discontinuation of dabigatran.
Four patients (2.5 %) experienced serious AEs during
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treatment with dabigatran (hepatic enzyme increase, renal
failure, myocardial infarction, and device dislocation).
Discussion
This study, performed in a “real-life” clinical setting,
sought to evaluate the safety and efficacy of a switch
from enoxaparin 40 mg qd to dabigatran 220 mg qd for
prevention of VTE after elective hip or knee replace-
ment surgery. The frequency and types of reported AEs,
serious AEs, and AEs leading to discontinuation of dabi-
gatran after switching from LMWH, were consistent
with the known safety profile for dabigatran. The inci-
dence of bleeding events was low and no symptomatic
VTE occurred. The switch from enoxaparin to dabiga-
tran was well tolerated. The study did not detect any
new safety issues when switching from LMWH to dabi-
gatran in patients undergoing elective orthopedic sur-
gery. The AEs and serious AEs were within the ranges
reported in earlier clinical trials with dabigatran. Thus,
these observational data support the feasibility and safety
of switching from enoxaparin to dabigatran.
The feasibility of switching from LMWH to NOAC is
an important, clinically relevant question in orthopedic
practice [4, 21, 25]. In the 9th edition of the American
College of Clinical Pharmacology (ACCP) guidelines,
NOACs have been included in the list of antithrombotic
therapies to be considered for patients undergoing total
hip arthroplasty or total knee arthroplasty surgery [4].
Although different guidelines exist regarding the preven-
tion of VTE in orthopedic surgery, no consensus has been
achieved on whether the optimal start of LMWH is pre-,
peri- or postoperative. The preferred timing of initiation
of thromboprophylaxis varies among countries and has
been extensively debated [26]. A perioperative start is ap-
parently more effective, but this is counterbalanced by a
marked increase in the risk of major bleeding in compari-
son with a preoperative or postoperative regimen [21].
The procedure of switching from enoxaparin to dabi-
gatran has been evaluated in healthy volunteers in an
earlier study [27]. Prior administration of enoxaparin for
3 days did not meaningfully affect the pharmacokinetic
or pharmacodynamic properties of dabigatran. The ra-
tios of free versus total dabigatran were not changed by
pretreatment with enoxaparin and no drug-related AEs,
such as any bleeding or hematoma, were observed.
Clinical experience regarding switching has also been
obtained in studies designed for the treatment of an
acute VTE. In the phase 3 RE-COVER study, all subjects
were initially treated with a parenteral anticoagulant,
mostly LMWH, which was applied at a higher dose than
for VTE prevention [24, 28]. Parenteral anticoagulation
was administered for ≥5 days together with either war-
farin or warfarin placebo, until the international normal-
ized ratio was ≥2 at 2 consecutive measurements. The
parenteral anticoagulant was then discontinued and pa-
tients either continued warfarin or were switched to dabiga-
tran 150 mg twice daily. The first dabigatran dose was
given 0–2 h before the time when the next dose of the par-
enteral therapy would have been due. In this study, during
the 6-month treatment period, there were fewer major or
clinically relevant nonmajor bleeding events and similar
rates of MBEs in the dabigatran group compared with the
warfarin group [24, 28]. This study demonstrated the effi-
cacy and safety of switching to dabigatran 150 mg twice
Table 1 Demographic data of all 168 patients included in the study
THR TKR Total
Treated, n (%) 81 (100.0) 87 (100.0) 168 (100.0)
Gender, n (%)
Male 40 (49.4) 32 (36.8) 72 (42.9)
Female 41 (50.6) 55 (63.2) 96 (57.1)
Age (years), median (Q1, Q3) 60.0 (52.0, 66.0) 64.0 (57.0, 69.0) 62.0 (55.0, 68.0)
Age class, n (%)
<65 years 55 (67.9) 47 (54.0) 102 (60.7)
65-75 years 26 (32.1) 39 (44.8) 65 (38.7)
>75 years 0 1 (1.1) 1 (0.6)
Body mass index (kg/m2), median (Q1, Q3) 27.2 (24.3, 29.8) 29.8 (26.8, 34.3) 28.4 (25.7, 32.5)
Body mass index class, n (%)
<25 kg/m2 25 (30.9) 11 (12.6) 36 (21.4)
25 – <30 kg/m2 37 (45.7) 33 (37.9) 70 (41.7)
30–35 kg/m2 11 (13.6) 26 (29.9) 37 (22.0)
>35 kg/m2 8 (9.9) 17 (19.5) 25 (14.9)
Q Quartile, THR Total hip replacement, TKR Total knee replacement
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daily in this patient population, even after the shorter time
frame of 12 h after the last dose of enoxaparin.
In addition, the safety of switching was investigated
in patients with atrial fibrillation (RE-LY trial of dabi-
gatran 150 or 110 mg twice daily versus warfarin), when
treatment for surgery or a diagnostic procedure was inter-
rupted temporarily by the investigators [29]. According to
the study protocol, discontinuation of dabigatran for be-
tween 1 and 5 days was recommended depending on the
type of procedure and the anticipated bleeding risk, and
short-term bridging anticoagulant therapy (e.g., LMWH)
was used, if appropriate. Temporary interruptions oc-
curred in 4623 patients. Stroke, myocardial infarction, and
bleeding events were similar in all treatment groups
within 30 days of reinitiating study medication. The au-
thors concluded that switching between a parenteral anti-
coagulant and dabigatran resulted in effective and safe
management of patients.
Furthermore, a clinical trial investigating the effects of
switching from enoxaparin to the new oral factor Xa in-
hibitor, rivaroxaban, in patients undergoing THR or
TKR has been published [30]. In 56 patients, the authors
found no cases of VTE or bleeding, and no unexpected
AEs, if rivaroxaban was initiated 12 or 24 h after the last
LMWH dose.
Current prescribing information for dabigatran recom-
mends that the anticoagulant should be initiated orally
within 1–4 h of completed surgery if hemostasis has been
obtained. This regimen has been successfully applied in
the RE-NOVATE, RE-NOVATE II and RE-MODEL stud-
ies [16–18]. However, this is not always possible. In this
present study, anticoagulation was started with LMWH
and the process of switching to dabigatran was left to the
decision of the treating physician. The median time of the
first dabigatran tablet was 24.0 h after the last LMWH
dosage and nearly three-quarters of patients got the first
Table 2 Patient characteristics related to first intake of dabigatran
THR TKR Total
Treated 81 87 168
Time from last enoxaparin to first dose dabigatran (hours)
N 79 82 161
Median (Q1, Q3) 24.0 (24.0, 24.0) 24.0 (24.0, 24.0) 24.0 (24.0, 24.0)
Minimum 9 4 4
Maximum 48 48 48
Time from last enoxaparin to first oral dose class (n [%])
0 – <14 hours 2 (2.5) 6 (7.3) 8 (5.0)
14 – <22 hours 4 (5.1) 2 (2.4) 6 (3.7)
22 – <26 hours 65 (82.3) 59 (72.0) 124 (77.0)
≥26 hours 8 (10.1) 15 (18.3) 23 (14.3)
Missing 2 (2.5) 5 (5.7) 7 (4.2)
Time to first oral dose after end of surgery (hours)
N 79 83 162
Median (Q1, Q3) 35.0 (31.3, 101.7) 33.6 (29.0, 99.3) 34.3 (29.8, 99.5)
Time to first oral dose after end of surgery class
Prior to end of surgery 0 0 0
0 – <1 hours 1 (1.2) 0 1 (0.6)
1 – <4 hours 4 (4.9) 5 (5.7) 9 (5.4)
4 – <8 hours 0 3 (3.4) 3 (1.8)
8 – <24 hours 0 0 0
≥24 hours 74 (91.4) 75 (86.2) 149 (88.7)
Missing 2 (2.5) 4 (4.6) 6 (3.6)
Relationship of first dabigatran dose to date of discharge (n [%])
1 or more days before discharge 68 (84.0) 67 (77.0) 135 (80.4)
On day of, or 1 day after, discharge 10 (12.3) 10 (11.5) 20 (11.9)
Missing 3 (3.7) 10 (11.5) 13 (7.7)
Q Quartile
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dabigatran dosage between 22 h and 26 h after last
LMWH dosage. While some delays in therapy were due
to clinical reasons (bleeding, drainage, or vomiting), the
majority were for logistical reasons, including late-day sur-
gery, organization of the ward, and nursing error. If initi-
ation of dabigatran therapy is delayed, it can be started
with a half-dose >4 h postsurgery if therapy begins on the
same day as surgery, or, with the full dose the day after
surgery. Eriksson BI, et al. investigated the effect of delay-
ing the initiation of oral therapy with dabigatran and
found that the efficacy in patients with a delay in the ad-
ministration of the 220 mg qd dose was similar to that in
patients without delayed dosing, even if the dose was de-
layed until the day after surgery [31].
Conclusions
This study addressed the feasibility of switching from the
LMWH, enoxaparin, to oral therapy with dabigatran, and
closed a gap that has not been investigated in detail in
phase 3/4 clinical trials for dabigatran in orthopedic sur-
gery. The switching procedure did not raise any new safety
issues or efficacy problems. The observed AEs were con-
sistent with the known safety profile of dabigatran.
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